This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Looking into the Phase 2 clinical trial of ION224, a DGAT2 antisense inhibitor being developed by Ionis Pharma for the treatment of MASH
Ticker(s): IONSWho's the expert?
Institution: Northwest Gastroenterology Associates
- Currently manages 100 patients with GERD
Interview Goalto discuss the current standard of care and the potential of ION224, a DGAT2 antisense inhibitor being developed by Ionis Pharma for the treatment of MASH.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
